Stonebrook Private Inc. Sells 9,931 Shares of Johnson & Johnson $JNJ

Stonebrook Private Inc. lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 41.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 14,170 shares of the company’s stock after selling 9,931 shares during the period. Stonebrook Private Inc.’s holdings in Johnson & Johnson were worth $2,933,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of JNJ. North Dallas Bank & Trust Co. acquired a new position in Johnson & Johnson during the 4th quarter worth about $3,079,000. Swan Global Investments LLC lifted its holdings in Johnson & Johnson by 5.3% during the 4th quarter. Swan Global Investments LLC now owns 1,896 shares of the company’s stock worth $392,000 after buying an additional 96 shares during the period. Focus Partners Advisor Solutions LLC lifted its holdings in Johnson & Johnson by 12.8% during the 4th quarter. Focus Partners Advisor Solutions LLC now owns 62,134 shares of the company’s stock worth $12,859,000 after buying an additional 7,032 shares during the period. Westerkirk Capital Inc. lifted its holdings in Johnson & Johnson by 14.3% during the 4th quarter. Westerkirk Capital Inc. now owns 40,059 shares of the company’s stock worth $8,290,000 after buying an additional 5,000 shares during the period. Finally, X Square Capital LLC lifted its holdings in Johnson & Johnson by 2.0% during the 4th quarter. X Square Capital LLC now owns 6,672 shares of the company’s stock worth $1,381,000 after buying an additional 128 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 2.0%

JNJ stock opened at $236.88 on Wednesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The stock’s 50 day simple moving average is $231.76 and its 200 day simple moving average is $226.61. The company has a market cap of $570.22 billion, a P/E ratio of 27.39, a price-to-earnings-growth ratio of 2.27 and a beta of 0.26. Johnson & Johnson has a fifty-two week low of $149.04 and a fifty-two week high of $251.71.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. The firm had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The company’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, research analysts expect that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were issued a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a yield of 2.3%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio is presently 61.97%.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J’s $1 billion acquisition of Firefly Bio strengthens its oncology pipeline with Firelink DAC technology aimed at hard-to-treat KRAS-driven cancers, which could improve long-term growth prospects. Johnson And Johnson Buys Firefly Bio To Deepen Oncology Growth Story
• Positive Sentiment: NICE preliminarily recommended D-VRd for first-line treatment of transplant-ineligible multiple myeloma in the NHS, a potential commercial boost for J&J’s Darzalex franchise. J&J secures extended NICE approval for Darzalex following earlier refusal
• Positive Sentiment: Commentary around J&J’s strong oncology and MedTech execution, including recent product momentum, is helping fuel bullish sentiment and expectations for continued growth. Will Johnson & Johnson Stock Hit $300 This Year?
• Neutral Sentiment: J&J also presented at Goldman Sachs’ healthcare conference, but the transcript does not provide a clear new catalyst on its own. Johnson & Johnson (JNJ) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Broader sector articles highlighting healthcare as a defensive trade may provide background support, but they are not J&J-specific catalysts. Middle East Erupts Again: Buy these Healthcare ETFs Before the Next Strike
• Negative Sentiment: Some coverage noted patent and legal headwinds facing J&J, which remain a risk factor even as the company’s diversified business and pipeline help offset concerns. JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?

Analysts Set New Price Targets

Several brokerages have commented on JNJ. Sanford C. Bernstein lifted their target price on Johnson & Johnson from $225.00 to $251.00 and gave the stock a “market perform” rating in a report on Wednesday, April 15th. HSBC lifted their target price on Johnson & Johnson from $265.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Guggenheim lifted their target price on Johnson & Johnson from $244.00 to $266.00 and gave the stock a “buy” rating in a report on Monday, April 20th. Rothschild & Co Redburn lifted their target price on Johnson & Johnson from $180.00 to $210.00 and gave the stock a “neutral” rating in a report on Thursday, February 19th. Finally, Daiwa Securities Group boosted their price objective on Johnson & Johnson from $237.00 to $246.00 and gave the company an “outperform” rating in a research note on Thursday, April 16th. Twenty analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $253.04.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.